Pipeline
Innovation in motion
We are dedicated to ensuring a stable supply of premium pharmaceuticals globally. By challenging existing models and applying cutting-edge science, we have built an industry-leading pipeline in both pre-clinical and clinical stages.
Our use of advanced technologies, including efficient biomanufacturing systems, enables us to support the production of orphan drugs and other specialized therapies, meeting the needs of patients everywhere.
Code Generic name
Preclinical
Clinical trial
Application
Approval
JR-141*
Phase Application
Indication
JCR received approval for JR-141 for the treatment of patients with mucopolysaccharidosis type ll (MPS II), also known as Hunter syndrome, in Japan in March 2021
Mechanism
BBB-penetrating iduronate-2-sulfatase (rDNA origin)
*Approved in Japan
JR-171
Phase Clinical trial
Indication
JR-171 is currently under development for MPS Type I or Hurler syndrome
Mechanism
BBB-penetrating acid alpha-L iduronidase (rDNA origin)
JR-142
Phase Clinical trial
Indication
JR-142 is currently under development for pediatric growth hormone deficiency
Mechanism
Long-acting human growth hormone (rDNA origin)
JR-441
Phase Clinical trial
Indication
JR-441 is currently under development for MPS Type IIIA or Sanfilippo syndrome Type A
Mechanism
BBB-penetrating heparan N-sulfatase (rDNA origin)
JR-446
Phase Clinical trial
Indication
JR-446 is currently under development for MPS Type IIIB or Sanfilippo syndrome Type B
Mechanism
BBB-penetrating α-N-acetylglucosaminidase (rDNA origin)
JR-471
Phase Preclinical
Indication
JR-471 is currently under development for fucosidosis
Mechanism
BBB-penetrating α-L-fucosidase (rDNA origin)
“As Global Head of Clinical Development and General Manager for Europe and the USA, my focus is on advancing our mid-to-late-stage pipeline globally with unwavering dedication to patient-centric drug development. Our mission is to bring innovative medicines to physicians as quickly and safely as possible, ensuring we make a meaningful impact on patients’ lives.”
Anne Bechet
Global Head of Clinical Development and General Manager for Europe and the USA